Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2211-2219

  Hu, Xiao ^a   Dietz, Jessica D ^a   Xia, Chunsheng ^a   Knight, Delvin R ^a   Loging, William T ^a   Smith, Andrew H ^a   Yuan, Haodan ^a   Perry, David A ^a   Keiser, Joan ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; AMLODIPINE; ANACETRAPIB; ANGIOTENSIN II; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CP 529415; CP 532623; CYCLIC AMP; DALCETRAPIB; HYDROCORTISONE; LOSARTAN; NIFEDIPINE; PF 868348; QUINOLINE DERIVATIVE; STEROID 11BETA MONOOXYGENASE; TORCETRAPIB; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT;

ADRENAL CELL; ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RABBIT; STRUCTURE ACTIVITY RELATION; ADRENAL TUMOR; BIOLOGICAL MODEL; CALCIUM SIGNALING; CARCINOMA; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR FLUID; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADRENAL GLAND NEOPLASMS; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CALCIUM SIGNALING; CARCINOMA; CELL LINE, TUMOR; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROCORTISONE; INTRACELLULAR FLUID; MODELS, BIOLOGICAL; QUINOLINES; STEROID 11-BETA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66449084532     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1512     Document Type: Article

References (27)

1. Gordon DJ, Rifkind BM 1989 High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321:1311-1316
2. Barter PJ, Brewer Jr HB, Chapman MJ, Hennekens CH, Rader DJ, Tall AR 2003 Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167
3. Brewer Jr HB 2004 Increasing HDL cholesterol levels. N Engl J Med 350: 1491-1494
4. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A 1998 Effect of antisense oligonucleotides against cholesterylestertransferproteinonthedevelopmentofatherosclerosisincho- lesterol-fed rabbits. JBiol Chem 273:5033-5036
5. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H 2000 A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207
6. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ 2007 Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. JLipid Res 48:1263-1272
7. de Haan W, de Vries-van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M,Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC 2008 Torcetrapib does not reduce atherosclerosis beyond atorva- statin and induces more proinflammatory lesions than atorvastatin. Circulation 117:2515-2522
8. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ 2006 Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47:537-552
9. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP,Rader DJ2004Effectsofaninhibitorofcholesterylestertransfer protein on HDL cholesterol. N Engl J Med 350:1505-1515
10. McKenney JM, Davidson MH, Shear CL, Revkin JH 2006 Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. JAm Coll Cardiol 48:1782-1790
11. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B 2007 Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122
12. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM 2007 Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl JMed 356:1304-1316
13. KasteleinJJ, vanLeuvenSI, Burgess L, Evans GW, KuivenhovenJA, BarterPJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. NEngl JMed 356:1620-1630
14. Bots ML, VisserenFL, Evans GW, RileyWA, RevkinJH, Tegeler CH, Shear CL,DugganWT, VicariRM, GrobbeeDE, KasteleinJJ2007Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153-160
15. Davidson MH, McKenney JM, Shear CL, Revkin JH 2006 Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individ- ualswith below-averagehigh-densitylipoproteincholesterollevels. JAmColl Cardiol 48:1774-1781
16. DePasquale M, Knight D, Loging W, Morehouse L, Winter S, Blasi E, Keiser J,Mechanisticstudiesofhemodynamicswithaseriesofcholesterylestertrans- fer protein inhibitors. Late Breaking Science Session 12. Proc American Heart Association Scientific Sessions, Orlando, FL, 2007 (Abstract)
17. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif- Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker 3rd M, West SH, White V, Woltmann RF 2008 Torce- trapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465-1473
18. Parmar J, Key RE, Rainey WE 2008 Development of an adrenocorticotropin- responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab 93:4542-4546
19. Romero DG, Rilli S, Plonczynski MW, Yanes LL, Zhou MY, Gomez-Sanchez EP, Gomez-Sanchez CE 2007 Adrenal transcription regulatory genes modulated by angiotensin II and their role in steroidogenesis. Physiol Genomics 30:26-34
20. Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE 2004 The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol Endocrinol 18:279-290
21. Aguilera G, Catt KJ1986 Participationofvoltage- dependentcalciumchannels in the regulation of adrenal glomerulosa function by angiotensin II and potassium. Endocrinology 118:112-118
22. Stowasser M 2001 New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 28:783-791
23. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J1999 Theeffectofspironolactoneonmorbidityandmortalityinpatientswith severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl JMed 341:709-717
24. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl JMed 348:1309-1321
25. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angio- tensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213-2220
26. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M 2005 Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46: 1135-1139
27. Spat A, Hunyady L 2004 Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 84:489 -539